HomeAI · summaries
Storia in 11 fonti
AstraZeneca shares slide after Ionis-partnered drug fails late-stage heart disease trial
AstraZeneca shares fell after Wainua failed a key trial. The drug did not reduce cardiovascular deaths or heart problems. Wainua showed no effect in patients already on stabilizer therapy. A subgroup taking the drug without stabilizers showed a nominal benefit. This setback impacts a projected two billion dollar sales opportunity.
Confronto fonti
6 prospettive sulla stessa storiaTimeline cronologica
- ·
cnbc.com
AstraZeneca stock dives 9% after heart drug trial misses target
A late-stage clinical trial failed to miss its primary endpoint, U.K.'s laregst drugmaker said Thursday.
- ·
thehindubusinessline.com
AstraZeneca’s Wainua fails main goal in late-stage heart disease trial
Drug developed with Ionis could not reduce cardiovascular deaths or recurring heart problems
